{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schmid AM"],"funding":["BioTechMed-Graz Flagship","Austrian Science Fund FWF","European Union","The Government of Lower Austria","OeAD WTZ","OeAD-GmbH"],"pagination":["297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10588034"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>E. coli O83 (Colinfant Newborn) is a Gram-negative (G-) probiotic bacterium used in the clinic. When administered orally, it reduces allergic sensitisation but not allergic asthma. Intranasal administration offers a non-invasive and convenient delivery method. This route bypasses the gastrointestinal tract and provides direct access to the airways, which are the target of asthma prevention. G- bacteria such as E. coli O83 release outer membrane vesicles (OMVs) to communicate with the environment. Here we investigate whether intranasally administered E. coli O83 OMVs (EcO83-OMVs) can reduce allergic airway inflammation in mice.<h4>Methods</h4>EcO83-OMVs were isolated by ultracentrifugation and characterised their number, morphology (shape and size), composition (proteins "],"journal":["Cell communication and signaling : CCS"],"pubmed_title":["Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice."],"pmcid":["PMC10588034"],"funding_grant_id":["RS 08/2022","DK W1248-B30","Project Secretome","CZ 06/2020","P 33073","Danube Allergy Research Cluster","101066450","P 34867","CZ 07/2023"],"pubmed_authors":["Schild S","Schabussova I","Kerekes D","Inic-Kanada A","Wysmolek M","Thaler M","Schmidt K","Wiedermann U","Kohl P","Haunstetter M","Palmfeldt J","Nejsum P","Weinmayer T","Geissler N","Whitehead B","Sindelar M","Hrdy J","Razim A","Schmid AM","Brazhnikov G","Krcmarova E"],"additional_accession":[]},"is_claimable":false,"name":"Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice.","description":"<h4>Background</h4>E. coli O83 (Colinfant Newborn) is a Gram-negative (G-) probiotic bacterium used in the clinic. When administered orally, it reduces allergic sensitisation but not allergic asthma. Intranasal administration offers a non-invasive and convenient delivery method. This route bypasses the gastrointestinal tract and provides direct access to the airways, which are the target of asthma prevention. G- bacteria such as E. coli O83 release outer membrane vesicles (OMVs) to communicate with the environment. Here we investigate whether intranasally administered E. coli O83 OMVs (EcO83-OMVs) can reduce allergic airway inflammation in mice.<h4>Methods</h4>EcO83-OMVs were isolated by ultracentrifugation and characterised their number, morphology (shape and size), composition (proteins ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Oct","modification":"2026-05-28T11:14:31.52Z","creation":"2026-05-13T14:22:22.345Z"},"accession":"S-EPMC10588034","cross_references":{"pubmed":["37864211"],"doi":["10.1186/s12964-023-01329-4"]}}